Results 261 to 270 of about 1,273,742 (384)
Regulatory T cell therapy for xenotransplantation, what perspectives? [PDF]
Porret R +10 more
europepmc +1 more source
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source
Commentary on: The Impact of Hypothermic Oxygenated Perfusion (HOPE) on Immune Responses and Sterile Inflammation in a Preclinical Model of Pancreatic Transplantation by Mesnard B et al. <i>Transplantation Direct</i> 2025; 11:e1743; doi: 10.1097/TXD.0000000000001743. [PDF]
Panisello-Rosello A +3 more
europepmc +1 more source
Aspects of corneal transplant immunology
Mehran Zarei-Ghanavati, Christopher Liu
openaire +4 more sources
Expert Perspective: Diagnosis and Treatment of Castleman Disease
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen +2 more
wiley +1 more source
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene M. Mekinian +111 more
wiley +1 more source
Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome. [PDF]
Campodonico E +20 more
europepmc +1 more source
B cells and systemic sclerosis interstitial lung disease
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman +2 more
wiley +1 more source

